While there is some evidence that Crizotinib can affect esophageal cancer with MET mutations, Crizotinib shows a marked antitumor action both in vitro and in vivo specifically in gastric cancer cells positive for MET amplification. There is very little clicnal information at this time, however. Crizotinib was administered to 4 patients with MET-amplified esophagogastric adenocarcinomas in part of a phase I study. Two patients had tumor shrinkage (16% and 30%) with PFS of 3.5 and 3.7 mo, respectively *Lennerz et al). As ntoed, this was a pahse I study, and I did not find any published studies in esophageal cancer.

CLINICAL / MEDICAL REFERENCES

Okamoto W¹, Okamoto I, Arao T, Kuwata K, Hatashita E, Yamaguchi H, Sakai K, Yanagihara K, Nishio K, Nakagawa K. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64..

Mikito Inokuchi, Sho Otsuki, Yoshitaka Fujimori, Yuya Sato, Masatoshi Nakagawa, and Kazuyuki Kojima,

Clinical significance of MET in gastric cancer. World J Gastrointest Oncol. 2015 Nov 15; 7(11): 317–327.

Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011;29:4803–4810

Targeted therapy in gastroesophageal cancers: past, present and future. Gastroenterol. Rep. (2015)doi: 10.1093/gastro/gov052